Furthermore, a high expression level of UBE2C was associated with shorter DSS in TSCC patients with poor cell differentiation (p = 0.042; Table 2), advanced pathological stage (p = 0.001; Table 2), lymph node metastasis (p = 0.041; Table 2) and postoperative radiation therapy (p = 0.002; Table 2). The gene discussed is UBE2C; the disease is metastatic malignant neoplasm in the lymph nodes.